AMILI

About AMILI

AMILI is a Singapore-based healthcare startup focused on advancing human health through microbiome science. The company is pioneering the creation of the first and largest multi-ethnic microbiome database in Asia. This database aims to support fundamental research into the impact of the gut microbiome on human health, particularly within the diverse populations of Asia.

AMILI serves a wide range of clients, including medical practitioners, patients, donors, and concerned citizens. Medical practitioners can use AMILI's data and insights to better understand and treat digestive health issues. Patients benefit from more personalized and effective treatments. Donors, particularly stool donors, play a crucial role in helping AMILI gather the necessary data to advance their research. Concerned citizens can contribute to a broader understanding of health and wellness in their communities.

The market AMILI operates in is the healthcare and biotechnology sector, with a specific focus on microbiome science. This is a rapidly growing field that explores how the trillions of microorganisms living in our guts affect our overall health.

AMILI's business model is based on data collection, research, and partnerships. The company collects stool samples from donors to build its microbiome database. This data is then used for research purposes and can be shared with medical institutions, pharmaceutical companies, and other stakeholders interested in microbiome science. By providing valuable insights and data, AMILI generates revenue through research grants, partnerships, and possibly future commercialization of their findings.

In summary, AMILI is at the forefront of microbiome science in Asia, leveraging the diverse populations of the region to build a comprehensive database that can revolutionize healthcare. The company makes money through research collaborations and data partnerships, aiming to improve digestive health and overall wellness.